SnapWidget
Yes Please!
Advertisement
Previously untreated chronic lymphocytic leukemia (CLL) patients experienced increased progression-free and overall survival when treated with ibrutinib-rituximab compared to current standard chemoimmunotherapy. Rates of high grade adverse events were sim

by 2minmed · 7 years ago · via Instagram

Advertisement